Kane Biotech (KNE) Q4 2024 earnings summary

Executive summary

• Reported Q4 2024 revenue of $125,859, up from $57,788 in Q4 2023, mainly from contract animal health manufacturing for Dechra Veterinary Products.

• Net income for Q4 2024 was $227,321, reversing a net loss of ($1,522,425) in Q4 2023, aided by a deferred tax recovery.

• Full year 2024 revenue reached $2,080,879, a significant increase from $148,980 in 2023, driven by higher product revenue.

• Net loss for 2024 narrowed to ($3,161,097) from ($4,562,345) in 2023, with operating expenses rising due to compensation, consulting, and R&D costs.

• Strategic focus narrowed to four verticals of the coactiv+ biofilm dispersion wound care portfolio, with emphasis on the revyve product line in the U.S. market.

Financial highlights

• Q4 2024 gross loss was ($87,204) versus a gross profit of $34,300 in Q4 2023, impacted by $209,775 in inventory write-downs for DermaKB.

• Full year 2024 gross profit was $872,096, up from $109,470 in 2023, despite inventory write-downs.

• Q4 2024 operating expenses were $933,479, down from $1,292,635 in Q4 2023, due to lower short-term incentive expense.

• Full year 2024 operating expenses rose to $4,795,093 from $3,466,856 in 2023, mainly from higher compensation, consulting, and R&D costs, and patent asset write-downs.

Outlook and guidance

• Focused on U.S. relaunch and clinician engagement for revyve, with new data generation planned for 2025.

• Regulatory approval for coactiv+ Antimicrobial Surgical Hydrogel and revyve Antimicrobial Wound Rinse forecasted in 2026.

• Cost reduction initiatives implemented, including reduced overhead and resource allocation.

• Clinical study for DispersinB Acne Cleanser delayed to 2026; less resources dedicated to DispersinB Hydrogel development in 2025.